Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program ( <scp>EAP</scp> )
Akimichi Morita(Nagoya City University), Keiichi Yamanaka(Mie University), Rafael Sani Simões(Boehringer Ingelheim (China)), Yuichiro Tsunemi(Saitama Medical University), Morihisa Saitoh(Boehringer Ingelheim (Japan)), Takuro Kanekura(Kagoshima University), M. Komine(Jichi Medical University), Yayoi Tada(Teikyo University), Nichiren Pillai(Boehringer Ingelheim (China)), Xuemei Ding(Boehringer Ingelheim (China)), Shinichi Imafuku(Fukuoka University Hospital), Nora Pöntynen(Institute for Molecular Medicine Finland), Toshiya Takahashi(Tohoku University)
Cited by 2
Related Papers
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials
|British Journal of Dermatology|2020|389
Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy
|Annals of the Rheumatic Diseases|2012|266
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
|Arthritis & Rheumatology|2016|119
Psoriasis and Antimicrobial Peptides
|International Journal of Molecular Sciences|2020|114
An In Vitro Test to Screen Skin Sensitizers Using a Stable THP-1–Derived IL-8 Reporter Cell Line, THP-G8
|Toxicological Sciences|2011|93